[HTML][HTML] Protective effects and mechanisms of Lizhong decoction (理中汤) against non-alcoholic fatty liver disease in a rat model

Y Jiayao, TAO Dongqing, MA Wei… - Journal of Traditional …, 2022 - ncbi.nlm.nih.gov
… Potential therapeutic targets for NAFLD were analyzed using network pharmacology. Liver
pathology was evaluated using Oil Red O and hematoxylin-eosin staining. Furthermore, …

[引用][C] Th17 细胞的分化调控及其在炎症性肠病中的作用

解莹, 李岩 - 中国免疫学杂志, 2021

[HTML][HTML] 基于网络药理学和蛋白模块分析淫羊藿治疗骨关节炎的作用与机制

章晓云, 张驰, 宋世雷, 韩杰, 陈跃平, 杨楠, 许灿宏 - 中国组织工程研究, 2020 - cjter.com
… A drug-component-target-disease network was then … targets of Epimedium and 1 221
therapeutic targets of osteoarthritis were predicted. After crossing, 95 therapeutic targets of …

[引用][C] 转铁蛋白与动脉粥样硬化发病相关性研究及抗动脉粥样硬化候选药物研发

唐小芃 - 2019

[引用][C] E3 泛素连接酶HECTD3 在乳腺癌转移与天然免疫中的功能机制研究

李富兵 - 2019

黑匣子之外的思考: 脑内皮细胞是阿尔茨海默病的新主要靶点吗?

E Estudillo, A López-Ornelas… - 中国神经再生研究 …, 2023 - sjzsyj.com.cn
… brain endothelial cells be appreciated as a therapeutic target instead of solely an obstacle
for delivering treatments to the injured brain in Alzheimer’s disease. Key Words: dementia; …

[HTML][HTML] 慢性鼻窦炎的内型研究及临床应用

孙立薇, 朱冬冬, 孟粹达 - Journal of Clinical Otorhinolaryngology …, 2020 - ncbi.nlm.nih.gov
… Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory disease with an as-… disease
progression, recurrence and comorbidities, as well as identify appropriate therapeutic targets

维生素D 受体在系统性红斑狼疮中的免疫调节作用研究进展

明希希, 王涛 - 蚌埠医学院学报, 2023 - xuebao.bbmc.edu.cn
… Hypoxia-inducible factor-1α: a promising therapeutic target for autoimmune diseases [J].
Expert Opinion Therapeutic Targets, 2017, 21 (7): 715. doi: 10.1080/14728222.2017. 1336539 …

调节性T 细胞—动脉粥样硬化治疗的新靶点

凌秋洋, 宗刚军 - 心脏杂志, 2014 - heartj.cn
… Abstract: The concept that atherosclerosis (AS) is a chronic inflammatory disease of the
arterial wall has been widely accepted and the immune system has been reported to play an …

炎症性肠病治疗目标的演变

葛文松 - 中华消化病与影像杂志(电子版), 2019 - zhxhbyyxzz.cma-cmc.com.cn
… of disease efficacy.This review mainly introduces the evolution of therapeutic targets for
IBD and the significance of mucosal healing and deep remission as therapeutic targets